Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Oct 20;9:208. doi: 10.1186/1748-717X-9-208

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Miyake et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Changes in serum PSA levels of patients who underwent salvage radiotherapy (SRT) for recurrent disease after radical prostatectomy. Patients were evaluated by PSA measurement at regular intervals after completing SRT. Patients who showed a decline to PSA < 0.2 ng/mL after SRT and maintained PSA < 0.2 ng/mL during the follow-up were categorized as the SRT success group (left). Patients who showed a decline to PSA < 0.2 ng/mL after SRT and thereafter experienced a rise in PSA at two consecutive measurement points with the last PSA ≥ 0.2 ng/mL (middle) were categorized as the recurrence group. If the PSA continued to rise without a decline to PSA < 0.2 ng/mL after SRT, patients were categorized as the nonresponse group (right). The recurrence group and the nonresponse group were defined as the SRT failure group.